PDCD1 and neutropenia: The most common AEs ≥ grade 3 of the two regimens are hematological toxicity (lymphocytopenia, leukopenia, and neutropenia), and hematological toxicity of grade 3 or above occurred in 40.0% (12 of 30) of Anti-PD-1+CRT group and 27.5% (14 of 51) of CRT group (P = 0.243).